VBI Vaccines Announces PreHevbri Is Now Available In The Netherlands And Belgium For The Prevention Of Hepatitis B In Adults
Portfolio Pulse from Benzinga Newsdesk
VBI Vaccines Inc. (NASDAQ:VBIV) has announced that its 3-antigen hepatitis B vaccine, PreHevbri, is now available in the Netherlands and Belgium. The product will be launched via marketing and distribution partner, Valneva. The company expects to continue expanding global access to PreHevbri with additional market launches in the coming months.
July 19, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
VBI Vaccines' PreHevbri is now available in the Netherlands and Belgium, potentially increasing the company's market share and revenues.
The availability of PreHevbri in the Netherlands and Belgium expands VBI Vaccines' market reach, potentially leading to increased sales and revenues. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100